University of North Carolina at Chapel Hill

Adhesion G protein-coupled receptors (2026) Langenhan T, Anderson GR, Araç D, Aust G, Avila-Zozaya M, Bagger SM, Barth P, et al. Journal article, Review article Large Library Docking for Polypharmacology (2026) Wu Y, Vigneron S, Braz J, Srinivasan K, Fink EA, Huang XP, Xu X, et al. Journal article Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial (2026) Mann JF, Marx N, Deanfield JE, Emerson SS, Inzucchi SE, McGuire DK, Mulvagh SL, et al. Journal article World Federation of Societies of Biological Psychiatry (WFSBP) consensus statement on candidate biomarkers for anorexia nervosa (2026) Himmerich H, Keeler JL, King JA, Ehrlich S, Kaufmann LK, Bulik CM, Cohen-Woods S, et al. Journal article, Review article Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes (2026) Pop-Busui R, Rasmussen S, Deanfield JE, Buse JB, Marx N, Mulvagh SL, Inzucchi SE, et al. Journal article Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial (2026) Agarwal R, Green JB, Heerspink HJ, McGill JB, Mottl A, Nangaku M, Rosenstock J, et al. Journal article Guidelines for Neuroprognostication in Critically Ill Adults with Status Epilepticus (2026) Madzar D, Rajajee V, Muehlschlegel S, Wartenberg KE, Alexander SA, Busl KM, Creutzfeldt CJ, et al. Journal article Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial (2026) Vaduganathan M, Green JB, Heerspink HJ, Kim SG, Mann JF, McGill JB, Mottl A, et al. Journal article Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials (2026) Müller-Wieland D, McGuire DK, Lincoff AM, Buse JB, Mann JF, Inzucchi SE, Pop-Busui R, et al. Journal article Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) (2025) Agarwal R, Green JB, Heerspink HJ, Mann JF, McGill JB, Mottl AK, Nangaku M, et al. Journal article